Le Lézard
Classified in: Health
Subjects: PSF, CFG, MAT

Advisory - Only use authorized nicotine pouches as directed, and do not use unauthorized nicotine pouches


OTTAWA, ON, March 20, 2024 /CNW/ - 

Summary
Affected Products

Nicotine pouches

Nicotine pouches (CNW Group/Health Canada (HC))

Issue

Health Canada is reminding consumers, including parents and caregivers of teens:

Nicotine pouches are authorized only as a nicotine replacement therapy to help adults quit smoking.

Using nicotine pouches in ways that have not been authorized, or using products that have not been authorized by Health Canada, may pose serious health risks, including the risk of addiction and nicotine overdose.

Risks of Nicotine:

Nicotine is a highly toxic and powerfully addictive substance. Children and teenagers are especially susceptible to the addictive properties of nicotine as brain development continues throughout adolescence and into early adulthood. Even using small amounts of nicotine may increase the risk of developing a dependence on nicotine in the future.

Excessive amounts of nicotine can cause acute poisoning, which can lead to severe breathing problems, and in the most serious cases, death. Symptoms of nicotine overdose include nausea, vomiting, stomach upset, fatigue, severe headache, dizziness, severe heartburn, cold sweats, blurred vision, weakness, fainting, mental confusion, irregular heart beat, palpitations and chest pain. The most common side effects of nicotine products are constipation, dry mouth, nervousness, headache, indigestion, and sleep disturbances. Consuming multiple nicotine products at the same time, including authorized nicotine replacement therapy products, or varenicline (a prescription smoking cessation drug), may increase the adverse effects of nicotine.

The dangers of using nicotine products are also especially high for people who are hypersensitive to nicotine, have never smoked or are occasional smokers, who are pregnant or nursing, or who have had recent heart problems (including heart attack, angina, arrhythmia) or a stroke.

Use authorized nicotine pouches only as directed:

To date, Health Canada has authorized only one nicotine pouch, containing 4 mg of nicotine per dose. This amount is usually recommended for adults who smoke 25 or more cigarettes a day who want to quit smoking.

Like most authorized nicotine replacement therapies, it is regulated as a natural health product and is available over the counter in most provinces and territories. Nicotine replacement therapies, including nicotine pouches, are not authorized for recreational use or for use by nonsmokers and people under 18 years old.

There are no authorized nicotine pouches in Canada that contain more than 4 mg of nicotine per dose.

Health Canada is concerned that some nicotine replacement therapies, including nicotine pouches, have become popular with youth and may lead to addiction. While there are already requirements for labelling, packaging and advertising of all nicotine replacement therapies to reflect their authorized clinical use and to prevent their appeal to youth, Health Canada is pursuing legislative and regulatory mechanisms to put in place safeguards.

Do not buy or use unauthorized nicotine pouches:

Health Canada continues to receive reports that unauthorized nicotine products are being sold at convenience stores, gas stations and other retailers in Canada, as well as over the Internet. Unauthorized nicotine products have not been assessed by Health Canada for safety, efficacy and quality, and they should not be used. They may contain ingredients not listed on the product label, which increases the risk of serious adverse or allergic reactions, or interactions with other medications and foods.

To be legally sold in Canada, nicotine pouches need Health Canada authorization. Authorized nicotine pouches must have an 8-digit natural product number (NPN) on the label. Health Canada has previously warned about the health risks of unauthorized nicotine pouches.

Taking action against unauthorized products on the Canadian market:

The Department is working closely with partners, including the Canada Border Services Agency, the Royal Canadian Mounted Police, and provincial and territorial public health units, to prevent unauthorized nicotine products from reaching the public.

Health Canada Inspectors continue to work on identifying and seizing unauthorized products in retail locations across Canada.

Goods entering Canada are examined and inspected based on the risk to the health, safety and security of people in Canada. Packages that contain non-compliant health products may be seized or refused entry.

The objective of the Department's compliance and enforcement approach is to mitigate the risk to Canadians using the most appropriate level of intervention. 

What consumers should do

Également disponible en français

SOURCE Health Canada (HC)


These press releases may also interest you

at 09:05
Smart Meter, the leading supplier of Cellular Remote Patient Monitoring (RPM)tm solutions, has introduced a new version of the iGlucose, its patented cellular-connected glucose meter used by over 200,000 people with diabetes since 2019. The...

at 09:00
Today, the Honourable Gary Anandasangaree, Minister of Crown-Indigenous Relations; the Honourable Patty Hajdu, Minister of Indigenous Services and Minister responsible for FedNor; the Honourable Dan Vandal, Minister of Northern Affairs; and the...

at 08:05
GE HealthCare today unveiled SIGNA MAGNUS, an FDA 510(k) pending head-only magnetic resonance (MR) scanner designed to explore advancements in neuroscience, which have been restricted by the performance limitations of conventional whole-body MR...

at 07:00
To mark National Hospice Palliative Care Week, the Quebec Coalition for Palliative Care Access (the Coalition) is proud to celebrate the positive impact of palliative care on the well-being of people with life-limiting illness. Palliative care is...

at 06:00
A native born and trained Brazilian oncologist is in the forefront of a new era in the treatment of cancer patients with cutting edge proton therapy medical technology developed in Israel by P-Cure. "It is my dream to be able to bring the P-Cure...

4 mai 2024
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced results from a new analysis of the ATLAS trial, which estimates using Kaplan Meier...



News published on and distributed by: